Bolt Biotherapeutics Q1 2024 GAAP EPS $(0.28) Beats $(0.49) Estimate, Sales $5.30M Beat $2.06M Estimate
Portfolio Pulse from Benzinga Newsdesk
Bolt Biotherapeutics (NASDAQ:BOLT) reported Q1 2024 earnings with a GAAP EPS of $(0.28), surpassing the $(0.49) estimate, and sales of $5.30M, exceeding the $2.06M estimate. This represents a 190.25% increase in sales compared to the same period last year.
May 14, 2024 | 8:31 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Bolt Biotherapeutics reported a significant beat on both EPS and sales estimates for Q1 2024, with a notable year-over-year sales increase.
Beating EPS and sales estimates significantly, especially with a substantial year-over-year sales increase, is likely to be viewed positively by investors. This could lead to increased investor confidence and potentially drive the stock price up in the short term.
CONFIDENCE 90
IMPORTANCE 90
RELEVANCE 100